FDA warns researchers on claims of drug to detect brain disease

New York

THE developers of a new drug aimed at diagnosing chronic traumatic encephalopathy, the degenerative brain disease linked to repeated head trauma, are under scrutiny by the US Food and Drug Administration.

In February, the FDA's Office of Prescription Drug Promotion sent a letter to two researchers at UCLA warning them that they had improperly marketed their drug on the Internet and had made overstated claims about the drug's potential efficacy.